Developer docs
API playgroundTry for free, no card

Search company profiles

Adaptive Biotechnologies

Full company profile

uuid00024ab

Namestring
Adaptive Biotechnologies
Legal namestring
Adaptive Biotechnologies Corporation
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington, that translates the genetics of the adaptive immune system into clinical diagnostics and therapeutic discovery tools. Its core commercial product is clonoSEQ, the first FDA-cleared next-generation sequencing assay for minimal residual disease (MRD) monitoring, currently reimbursed for multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and more recently mantle cell lymphoma (MCL) under Medicare. The clonoSEQ assay detects residual cancer cells in bone marrow or blood at a sensitivity of one in a million cells (10⁻⁶) and is ordered by oncologists and hematologists for treatment-response assessment and disease-progression monitoring, with test volume reaching 105,587 in 2025.

The company's second business line is its Immune Medicine Platform, which combines immunosequencing, proprietary TCR-antigen mapping, and AI/ML to decode T-cell and B-cell receptor sequences against disease-specific antigens. The platform underpins the immuneCODE database and supports pharma partnerships for target discovery and clinical-trial biomarkers, most notably two December 2025 agreements with Pfizer with up to $890 million in potential milestone payments.

Adaptive generates revenue primarily through clinical diagnostic testing services billed to Medicare and commercial payers at an average selling price of approximately $1,400 per clonoSEQ test, supplemented by biopharma services (MRD testing and immune monitoring for clinical trials) and non-exclusive immune-receptor data licensing agreements with pharmaceutical partners. The MRD business contributed $212 million of 2025 revenue and reached positive adjusted EBITDA of $15 million, while full-year 2025 total revenue reached $277 million (55% YoY growth). The company operates a U.S.-focused direct sales and CLIA-certified laboratory model, with plans to expand internationally through technology transfer partnerships and to separate the MRD and Immune Medicine businesses into two distinct entities by year-end 2026.

Short descriptiontext

Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune sequencing diagnostics, minimal residual disease testing, T-cell receptor profiling, immune receptor mapping, clinical genomic diagnostics
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1MRD Testing (clonoSEQ)
TypeSubscription Recurring
Description

Revenue from clinical diagnostic testing services using clonoSEQ assay for minimal residual disease monitoring in blood cancer patients. Tests are ordered by oncologists and hematologists for patient monitoring during and after treatment. Q1 2026 MRD revenue was $67.1 million, representing 95% of total revenue.

finance.yahoo.com
2Pharma Partnerships - Immune Receptor Licensing
TypeLicensing Royalties
Description

Non-exclusive licensing agreements with pharmaceutical companies for T-cell receptor discovery and immune receptor data. December 2025 Pfizer agreements worth up to $890 million in potential milestone payments plus upfront payments. Includes target discovery partnership and data licensing for AI-driven drug discovery.

globenewswire.com
3Biopharma Services
TypeProfessional Services
Description

Services provided to pharmaceutical companies for clinical trials including MRD testing in drug development, immune monitoring, and clinical trial support. Growing pharma trial backlog supporting MRD-led growth.

fool.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1clonoSEQ MRD test - clinical diagnostic pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Average selling price projected at $1,400 per test based on TD Cowen conference guidance. Medicare and commercial insurance coverage available for FDA-cleared indications.

in.investing.com
2Pharma partnership and licensing agreements
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront payments plus potential milestone payments up to $890 million (Pfizer agreements). Royalties on development and commercialization.

globenewswire.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1clonoSEQ
Description

FDA-cleared NGS-based MRD test for measuring residual disease in blood cancers including multiple myeloma, B-ALL, and CLL

adaptivebiotech.com
+3 more records
Core offering1 text field

Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Patients with undetectable MRD had nearly 7-fold decreased risk of disease progression compared to MRD-positive patients
+3 more records
Product overview1 text field

Adaptive Biotechnologies operates a dual-segment business centered on its Immune Medicine Platform, which encompasses two core products: clonoSEQ and the Immune Medicine discovery business. clonoSEQ is an FDA-cleared NGS-based MRD test for measuring residual cancer cells in blood cancers, while the Immune Medicine Platform uses immune repertoire sequencing and AI-driven TCR-antigen models to support drug discovery and biopharma partnerships. The company recently announced plans to separate these two businesses into distinct entities. Key offerings include T-Detect COVID (a T-cell diagnostic for prior SARS-CoV-2 infection), immunoSEQ T-MAP COVID (a vaccine monitoring tool), and the newly launched Digital Biotechnologies subsidiary.

Product and service4 records
1clonoSEQ
CategoryClinical Diagnostics - MRD Testing
Description

FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in bone marrow and blood samples from patients with multiple myeloma, B-ALL, CLL, and other lymphoid malignancies at a sensitivity of 1 in 1,000,000 cells. Ordered by oncologists and hematologists, processed through Adaptive's CLIA-certified lab, and reimbursed by Medicare and commercial insurance.

2Immune Medicine Platform
CategoryImmune Medicine / Biopharma Services
Description

Proprietary immune repertoire sequencing platform that maps T-cell receptors (TCRs) to disease-specific antigens, enabling drug discovery partnerships and AI-driven target identification for immunology applications. Anchored by a database of over 6 million functional TCR-antigen pairs and used by pharmaceutical companies such as Pfizer for AI-driven drug discovery and TCR target identification.

3T-Detect COVID
CategoryClinical Diagnostics - Infectious Disease
Description

T-cell based clinical diagnostic test that detects prior SARS-CoV-2 infection by identifying virus-specific T-cell signatures in blood, offering higher sensitivity and durability than antibody serology testing.

4immunoSEQ T-MAP COVID
CategoryBiopharma Research Services / Immune Monitoring
Description

Molecular T-cell monitoring tool for vaccine developers that maps TCRs to SARS-CoV-2 antigens, enabling quantitative measurement of T-cell immune response to vaccines and tracking of response persistence over time.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Two non-exclusive licensing agreements: (1) T-cell receptor target discovery partnership for rheumatoid arthritis where Adaptive identifies disease-specific TCRs and Pfizer handles development and commercialization; (2) Data licensing agreement for Adaptive's proprietary TCR-antigen binding datasets to accelerate Pfizer's AI-driven drug discovery. Total potential milestone payments up to $890 million.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Exclusive multi-year MRD collaboration announced in 2026 for liquid biopsy and NGS panel offerings. NeoGenomics will offer MRD testing services using Adaptive's technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Sponsor partnership for MRD education initiatives targeting community oncology practices. Joint development of MRD Testing Implementation Roadmap for CLL and multiple myeloma.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for MRD education in community oncology. NCODA published Positive Quality Intervention for clonoSEQ in CLL.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natera markets Signatera, a leading tumor-informed NGS-based MRD test used in solid tumor monitoring and clinical trials. It is the most direct competitor to Adaptive's clonoSEQ in the MRD testing category, serving oncologists and biopharma sponsors with overlapping clinical use cases.

TypeDirect peer
Description

NeoGenomics provides oncology testing including liquid biopsy and NGS panels, and signed an exclusive multi-year MRD collaboration with Adaptive in 2026. It is both a partner and adjacent competitor in the community oncology MRD/liquid biopsy segment.

TypeDirect peer
Description

Guardant Health offers liquid biopsy-based oncology tests (Guardant360, Guardant Reveal MRD) for solid tumors. It competes with Adaptive in oncology diagnostics and shares the same hospital and biopharma customer base for cancer recurrence and monitoring.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling in oncology. It overlaps with Adaptive's immune profiling and biopharma services and serves many of the same academic cancer centers and pharma sponsors at broader scale.

TypeBroad incumbent
Description

Exact Sciences is a large cancer diagnostics company known for Cologuard and the Oncotype franchise. It is a broader incumbent in oncology screening and recurrence monitoring, competing for oncologist mind-share and biopharma services revenue.

6Tempus AI
TypeEmerging player
Description

Tempus AI combines genomic sequencing with AI-driven analytics for oncology and biopharma customers. Its AI platform, MRD-adjacent offerings, and pharma partnerships overlap with Adaptive's Immune Medicine business in particular.

TypeEmerging player
Description

Personalis is a cancer genomics company offering tumor and immune profiling for biopharma R&D and clinical trials. It overlaps with Adaptive's Immune Medicine/biopharma services segment around TCR-based and immune profiling data for pharma customers.

TypeEmerging player
Description

Caris provides molecular profiling and AI-driven oncology diagnostics, including liquid biopsy offerings that overlap with MRD monitoring. It targets similar oncologist and biopharma customer segments and represents an emerging competitor in cancer recurrence testing.

TypeBroad incumbent
Description

Myriad Genetics offers hereditary cancer and tumor profiling tests serving oncologists and urologists. While its focus is broader genetic testing, it competes for the same clinician customers and biopharma partnership economics.

TypeOthers
Description

10x Genomics provides single-cell and immune receptor sequencing tools that enable research applications. It is an enabling/infrastructure provider for the same immune sequencing ecosystem in which Adaptive operates rather than a direct competitor in MRD.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adaptive Biotechnologies

Clinical Diagnosticsadaptivebiotech.com

Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.

What Adaptive Biotechnologies does

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington, that translates the genetics of the adaptive immune system into clinical diagnostics and therapeutic discovery tools. Its core commercial product is clonoSEQ, the first FDA-cleared next-generation sequencing assay for minimal residual disease (MRD) monitoring, currently reimbursed for multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and more recently mantle cell lymphoma (MCL) under Medicare. The clonoSEQ assay detects residual cancer cells in bone marrow or blood at a sensitivity of one in a million cells (10⁻⁶) and is ordered by oncologists and hematologists for treatment-response assessment and disease-progression monitoring, with test volume reaching 105,587 in 2025.

The company's second business line is its Immune Medicine Platform, which combines immunosequencing, proprietary TCR-antigen mapping, and AI/ML to decode T-cell and B-cell receptor sequences against disease-specific antigens. The platform underpins the immuneCODE database and supports pharma partnerships for target discovery and clinical-trial biomarkers, most notably two December 2025 agreements with Pfizer with up to $890 million in potential milestone payments.

Adaptive generates revenue primarily through clinical diagnostic testing services billed to Medicare and commercial payers at an average selling price of approximately $1,400 per clonoSEQ test, supplemented by biopharma services (MRD testing and immune monitoring for clinical trials) and non-exclusive immune-receptor data licensing agreements with pharmaceutical partners. The MRD business contributed $212 million of 2025 revenue and reached positive adjusted EBITDA of $15 million, while full-year 2025 total revenue reached $277 million (55% YoY growth). The company operates a U.S.-focused direct sales and CLIA-certified laboratory model, with plans to expand internationally through technology transfer partnerships and to separate the MRD and Immune Medicine businesses into two distinct entities by year-end 2026.

Adaptive Biotechnologies firmographics

Firmographics
Name
Adaptive Biotechnologies
Legal name
Adaptive Biotechnologies Corporation
Website
https://adaptivebiotech.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.
Ownership category
akta.pro rank

Adaptive Biotechnologies industry classification

Industry
Product category
Clinical Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immune sequencing diagnostics
  • Minimal residual disease testing
  • T-cell receptor profiling
  • Immune receptor mapping
  • Clinical genomic diagnostics

Where Adaptive Biotechnologies is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Adaptive Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. MRD Testing (clonoSEQ): Revenue from clinical diagnostic testing services using clonoSEQ assay for minimal residual disease monitoring in blood cancer patients. Tests are ordered by oncologists and hematologists for patient monitoring during and after treatment. Q1 2026 MRD revenue was $67.1 million, representing 95% of total revenue.
  2. Pharma Partnerships - Immune Receptor Licensing: Non-exclusive licensing agreements with pharmaceutical companies for T-cell receptor discovery and immune receptor data. December 2025 Pfizer agreements worth up to $890 million in potential milestone payments plus upfront payments. Includes target discovery partnership and data licensing for AI-driven drug discovery.
  3. Biopharma Services: Services provided to pharmaceutical companies for clinical trials including MRD testing in drug development, immune monitoring, and clinical trial support. Growing pharma trial backlog supporting MRD-led growth.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goclonoSEQ MRD test - clinical diagnostic pricing
OtherMulti-year contractPharma partnership and licensing agreements

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Adaptive Biotechnologies product offering

Product offering

Core offering

Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.

Product overview

Adaptive Biotechnologies operates a dual-segment business centered on its Immune Medicine Platform, which encompasses two core products: clonoSEQ and the Immune Medicine discovery business. clonoSEQ is an FDA-cleared NGS-based MRD test for measuring residual cancer cells in blood cancers, while the Immune Medicine Platform uses immune repertoire sequencing and AI-driven TCR-antigen models to support drug discovery and biopharma partnerships. The company recently announced plans to separate these two businesses into distinct entities. Key offerings include T-Detect COVID (a T-cell diagnostic for prior SARS-CoV-2 infection), immunoSEQ T-MAP COVID (a vaccine monitoring tool), and the newly launched Digital Biotechnologies subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • clonoSEQ: FDA-cleared NGS-based MRD test for measuring residual disease in blood cancers including multiple myeloma, B-ALL, and CLL
  • T-Detect
  • immunoSEQ
  • immuneCODE

Products and services

  • clonoSEQ FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in bone marrow and blood samples from patients with multiple myeloma, B-ALL, CLL, and other lymphoid malignancies at a sensitivity of 1 in 1,000,000 cells. Ordered by oncologists and hematologists, processed through Adaptive's CLIA-certified lab, and reimbursed by Medicare and commercial insurance.
  • Immune Medicine Platform Proprietary immune repertoire sequencing platform that maps T-cell receptors (TCRs) to disease-specific antigens, enabling drug discovery partnerships and AI-driven target identification for immunology applications. Anchored by a database of over 6 million functional TCR-antigen pairs and used by pharmaceutical companies such as Pfizer for AI-driven drug discovery and TCR target identification.
  • T-Detect COVID T-cell based clinical diagnostic test that detects prior SARS-CoV-2 infection by identifying virus-specific T-cell signatures in blood, offering higher sensitivity and durability than antibody serology testing.
  • immunoSEQ T-MAP COVID Molecular T-cell monitoring tool for vaccine developers that maps TCRs to SARS-CoV-2 antigens, enabling quantitative measurement of T-cell immune response to vaccines and tracking of response persistence over time.

Quantifiable outcome

  • Patients with undetectable MRD had nearly 7-fold decreased risk of disease progression compared to MRD-positive patients
  • +3 more outcomes

Companies that use Adaptive Biotechnologies

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Adaptive Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Adaptive Biotechnologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Pfizer Inc.coreStrategic or Co-development Partner · 15 December 2025Two non-exclusive licensing agreements: (1) T-cell receptor target discovery partnership for rheumatoid arthritis where Adaptive identifies disease-specific TCRs and Pfizer handles development and commercialization; (2) Data licensing agreement for Adaptive's proprietary TCR-antigen binding datasets to accelerate Pfizer's AI-driven drug discovery. Total potential milestone payments up to $890 million.
  • NeoGenomicsminorStrategic or Co-development PartnerExclusive multi-year MRD collaboration announced in 2026 for liquid biopsy and NGS panel offerings. NeoGenomics will offer MRD testing services using Adaptive's technology.
  • ACCC (Association of Community Cancer Centers)minorStrategic or Co-development PartnerSponsor partnership for MRD education initiatives targeting community oncology practices. Joint development of MRD Testing Implementation Roadmap for CLL and multiple myeloma.
  • NCODA (National Community Oncology Dispensing Association)minorStrategic or Co-development PartnerPartnership for MRD education in community oncology. NCODA published Positive Quality Intervention for clonoSEQ in CLL.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Adaptive Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Natera: Natera markets Signatera, a leading tumor-informed NGS-based MRD test used in solid tumor monitoring and clinical trials. It is the most direct competitor to Adaptive's clonoSEQ in the MRD testing category, serving oncologists and biopharma sponsors with overlapping clinical use cases.
  • NeoGenomics: NeoGenomics provides oncology testing including liquid biopsy and NGS panels, and signed an exclusive multi-year MRD collaboration with Adaptive in 2026. It is both a partner and adjacent competitor in the community oncology MRD/liquid biopsy segment.
  • Guardant Health: Guardant Health offers liquid biopsy-based oncology tests (Guardant360, Guardant Reveal MRD) for solid tumors. It competes with Adaptive in oncology diagnostics and shares the same hospital and biopharma customer base for cancer recurrence and monitoring.

Broad incumbents

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling in oncology. It overlaps with Adaptive's immune profiling and biopharma services and serves many of the same academic cancer centers and pharma sponsors at broader scale.
  • Exact Sciences: Exact Sciences is a large cancer diagnostics company known for Cologuard and the Oncotype franchise. It is a broader incumbent in oncology screening and recurrence monitoring, competing for oncologist mind-share and biopharma services revenue.
  • Myriad Genetics: Myriad Genetics offers hereditary cancer and tumor profiling tests serving oncologists and urologists. While its focus is broader genetic testing, it competes for the same clinician customers and biopharma partnership economics.

Emerging players

  • Tempus AI: Tempus AI combines genomic sequencing with AI-driven analytics for oncology and biopharma customers. Its AI platform, MRD-adjacent offerings, and pharma partnerships overlap with Adaptive's Immune Medicine business in particular.
  • Personalis: Personalis is a cancer genomics company offering tumor and immune profiling for biopharma R&D and clinical trials. It overlaps with Adaptive's Immune Medicine/biopharma services segment around TCR-based and immune profiling data for pharma customers.
  • Caris Life Sciences: Caris provides molecular profiling and AI-driven oncology diagnostics, including liquid biopsy offerings that overlap with MRD monitoring. It targets similar oncologist and biopharma customer segments and represents an emerging competitor in cancer recurrence testing.

Others

  • 10x Genomics: 10x Genomics provides single-cell and immune receptor sequencing tools that enable research applications. It is an enabling/infrastructure provider for the same immune sequencing ecosystem in which Adaptive operates rather than a direct competitor in MRD.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Adaptive Biotechnologies social profiles

Digital presence

Adaptive Biotechnologies compliance and trust

Trust signal

Compliance3 records

Adaptive Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adaptive Biotechnologies leadership team

Management profile

Number of profiles

Profiles10 records

Adaptive Biotechnologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Adaptive Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adaptive Biotechnologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adaptive Biotechnologies

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.

Is Adaptive Biotechnologies a public or private company?

Adaptive Biotechnologies is a public company. It is classified as public and is currently operating.

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009. It employs 501 to 1,000 people.

Where is Adaptive Biotechnologies based?

Adaptive Biotechnologies is headquartered in Seattle, United States, in the North America region.

How does Adaptive Biotechnologies make money?

Three revenue lines are on record. MRD Testing (clonoSEQ) is the primary driver. The others are pharma Partnerships - Immune Receptor Licensing and biopharma Services.

Who are Adaptive Biotechnologies's main competitors?

Direct peers on record are Natera, NeoGenomics and Guardant Health. Broad incumbents are Foundation Medicine, Exact Sciences and Myriad Genetics. Emerging players are Tempus AI, Personalis and Caris Life Sciences. 10x Genomics is listed as an others.

Does Adaptive Biotechnologies have an API?

No public API is recorded for Adaptive Biotechnologies.

What industry is Adaptive Biotechnologies in?

Adaptive Biotechnologies's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanAdaptive Biotechnologies clonoSEQ set for ~100 ASH abstractsAdaptive Biotechnologies announced its clonoSEQ MRD test will be featured in approximately 100 abstracts, including 27 oral presentations, at ASH 2026 in New Orleans. The research spans 20 biopharma-sponsored studies, with MRD as a primary endpoint in four and secondary in 11. The company highlights its role in guiding treatment strategies across lymphoid malignancies.GlobeNewswireAdaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026Adaptive Biotechnologies announced its clonoSEQ MRD test will be featured in about 100 abstracts, including 27 oral presentations, at ASH 2026 in New Orleans. The test is used as a primary endpoint in four studies and a secondary endpoint in 11 across 20 biopharma-sponsored studies.Investing.comJulie Rubinstein, Adaptive Biotechnologies COO, sells $1M in stockJulie Rubinstein, COO of Adaptive Biotechnologies, sold shares totaling about $1.047 million in mid-November 2026, with option exercises also occurring. The company reported Q3 2026 revenue of $83.9 million, up 39% year-over-year, beating analyst estimates. The stock trades near its 52-week high of $32.21.Investing.comAdaptive Biotechnologies CCO Bobulsky sells $60,000 in stockAdaptive Biotechnologies CCO Susan Bobulsky sold 1,875 shares on November 11, 2026, for $60,000 at $32.00 each. The company reported Q3 revenue of $83.9 million, up 39% year-over-year, beating the $71.57 million forecast. The stock trades at $29.04, down from the sale price.The future of tradingAdaptive Biotechnologies President and COO Julie Rubinstein Sells $1.05 Million in Common SharesAdaptive Biotechnologies President and COO Julie Rubinstein sold 35,228 common shares between Nov. 11-13, 2026, at prices ranging from $28.93 to $31.22 per share. She also exercised stock options for the same number of shares at $12.14 per share, leaving her direct holdings at 377,802 shares.Simply Wall StHow Investors May Respond To Adaptive Biotechnologies (ADPT) DNA Sequencing SpotlightAdaptive Biotechnologies reported Q3 2026 revenue of $83.9 million and net income of $2.88 million, with nine-month revenue of $226.33 million and a net loss of $56.95 million. The company's MRD platform showed profitability, but overall losses persist as it invests in TCR antigen and AI data. Analysts forecast revenue of $484 million and earnings of $18.3 million by 2029.American Banking and Market NewsAdaptive Biotechnologies (NASDAQ:ADPT) Stock Gets Price Target Bump from GuggenheimGuggenheim raised its price target on Adaptive Biotechnologies from $32 to $34, keeping a buy rating. The stock opened at $29.94, and the consensus rating is Moderate Buy with a target of $30.31. Analysts forecast a loss of $0.29 per share for the current fiscal year.Investing.comAdaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stockAdaptive Biotechnologies COO Julie Rubinstein sold 23,762 shares for $708,557 on Nov 9-10, 2026, under a Rule 10b5-1 plan. She also exercised options to acquire 23,762 shares at $12.14 each. The company reported Q3 revenue of $83.9 million, up 39% year-over-year, beating estimates.Stock TitanAdaptive Biotechnologies plans two conference appearancesAdaptive Biotechnologies will present at the Jefferies Global Healthcare Conference in London on November 18, 2026, and a Piper Sandler fireside chat in New York on December 2, 2026. The company, a commercial-stage biotechnology firm, will host live and archived webcasts of both sessions.Simply Wall StAdaptive Biotechnologies (ADPT) Stock Looks Reasonable As Cash Flow Recovery Takes ShapeAdaptive Biotechnologies' stock is evaluated on cash flow recovery, with a DCF model projecting positive free cash flow in the late 2020s. The company's latest 12-month free cash flow is a loss of $9.1 million, but MRD revenue growth and a recent capital raise support the current share price of $30.26.